Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envolizumab plus chemotherapy for untreated advanced biliary tract tumors
ChiCTR2300074506Phase 2Recruiting
- Sponsor
- Affiliated Qingdao Central Hospital of Qingdao University
- Start
- Mar 2023
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of envafolimab in biliary cancer, sponsored by Affiliated Qingdao Central Hospital of Qingdao University. Primary endpoint: Objective response rate. Started Mar 2023; status: recruiting.
02
Drugs
envafolimab
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2300074506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074506.